Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Pacific Biosciences Q2 Adj. EPS $(0.13) Beats $(0.17) Estimate, Sales $39.766M Beat $36.886M Estimate

Author: Benzinga Newsdesk | August 07, 2025 04:12pm
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.98 percent. This is a 35 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $39.766 million which beat the analyst consensus estimate of $36.886 million by 7.81 percent. This is a 10.42 percent increase over sales of $36.013 million the same period last year.

Posted In: PACB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist